1 / 1

Patients 3-10 days post ACS without HF/LVSD but  natriuretic peptides

N=1101. Patients 3-10 days post ACS without HF/LVSD but  natriuretic peptides. Standard Medical Therapy. NT- proBNP & Aldosterone. Blinded Therapy. Placebo. Aliskiren. Valsartan. Valsartan /Aliskiren. 4 wks. Dose up-titration over 2 weeks. NT-proBNP.

yanni
Download Presentation

Patients 3-10 days post ACS without HF/LVSD but  natriuretic peptides

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. N=1101 Patients 3-10 days post ACS without HF/LVSD but  natriuretic peptides Standard Medical Therapy NT-proBNP & Aldosterone Blinded Therapy Placebo Aliskiren Valsartan Valsartan /Aliskiren 4 wks Dose up-titration over 2 weeks NT-proBNP Dose up-titration of 2nd agent over 2 weeks (placebo in 3 arms and active in combo arm) 4 wks NT-proBNP & Aldosterone End of Study Biomarker Endpoint: ∆ NT-proBNP and ∆ Aldosterone Clinical Endpoint: CV death, recurrent MI, HF hospitalization

More Related